“STAT+ Exclusive: Revolution Medicines' Daraxonrasib Leads Charge in Historic Race to Conqu” — what this page in the network covers. A STAT+ report highlights a fiercely competitive race to develop drugs targeting the notoriously difficult KRAS gene, a primary driver of pancreatic cancer... A STAT+ report highlights a fiercely competitive race to develop drugs targeting the notoriously difficult KRAS gene, a primary driver of pancreatic cancer. For decades, the mutated KRAS protein was considered "undruggable." However, new therapeutic approaches are showing unprecedented promise.
Revolution Medicines' experimental drug, daraxonrasib, is demonstrating remarkable success in early trials, reportedly doubling survival time for some patients, including those with the aggressive KRAS G12D mutation. This breakthrough offers a significant glimmer of hope in a field long plagued by low survival rates. The article details the scientific challenges, the competitive landscape with other major pharmaceutical players, and the critical next steps, including larger clinical trials and addressing potential resistance and accessibility issues. The full version stays on the original page, which this listing opens directly.